B
BIOREM Inc.
BRM.V
TSX
B
Buy
9/3/2024Upgraded
BIOREM Inc. (BRM.V) was upgraded to B from B- on 9/3/2024 due to a major increase in the growth index, solvency index and volatility index. Total revenue increased 21.55% from $4.39M to $5.34M, and debt to equity declined from 0.41 to 0.36.
BIOREM Inc. (BRM.V) was upgraded to B from B- on 9/3/2024 due to a major increase in the growth index, solvency index and volatility index. Total revenue increased 21.55% from $4.39M to $5.34M, and debt to equity declined from 0.41 to 0.36.
B
Buy
8/16/2024Downgrade
BIOREM Inc. (BRM.V) was downgraded to B- from B on 8/16/2024 due to a decline in the efficiency index, total return index and valuation index.
BIOREM Inc. (BRM.V) was downgraded to B- from B on 8/16/2024 due to a decline in the efficiency index, total return index and valuation index.
B
Buy
7/17/2024Upgraded
BIOREM Inc. (BRM.V) was upgraded to B from B- on 7/17/2024 due to an increase in the total return index, volatility index and valuation index.
BIOREM Inc. (BRM.V) was upgraded to B from B- on 7/17/2024 due to an increase in the total return index, volatility index and valuation index.
B
Buy
7/2/2024Downgrade
BIOREM Inc. (BRM.V) was downgraded to B- from B on 7/2/2024 due to a decline in the valuation index.
BIOREM Inc. (BRM.V) was downgraded to B- from B on 7/2/2024 due to a decline in the valuation index.
B
Buy
6/17/2024Upgraded
BIOREM Inc. (BRM.V) was upgraded to B from B- on 6/17/2024 due to an increase in the volatility index, total return index and valuation index.
BIOREM Inc. (BRM.V) was upgraded to B from B- on 6/17/2024 due to an increase in the volatility index, total return index and valuation index.
B
Buy
6/10/2024Upgraded
BIOREM Inc. (BRM.V) was upgraded to B- from C+ on 6/10/2024 due to a major increase in the growth index, volatility index and valuation index. Operating cash flow increased 10,889.01% from $28.2 to $3.1M.
BIOREM Inc. (BRM.V) was upgraded to B- from C+ on 6/10/2024 due to a major increase in the growth index, volatility index and valuation index. Operating cash flow increased 10,889.01% from $28.2 to $3.1M.
C
Hold
4/17/2024Upgraded
BIOREM Inc. (BRM.V) was upgraded to C+ from C on 04/17/2024.
BIOREM Inc. (BRM.V) was upgraded to C+ from C on 04/17/2024.
C
Hold
5/23/2023Downgrade
BIOREM Inc. (BRM.V) was downgraded to C from B- on 5/23/2023 due to a decline in the total return index and efficiency index.
BIOREM Inc. (BRM.V) was downgraded to C from B- on 5/23/2023 due to a decline in the total return index and efficiency index.
B
Buy
4/6/2023Downgrade
BIOREM Inc. (BRM.V) was downgraded to B- from B on 4/6/2023 due to a significant decline in the growth index and valuation index.
BIOREM Inc. (BRM.V) was downgraded to B- from B on 4/6/2023 due to a significant decline in the growth index and valuation index.
B
Buy
3/30/2023Upgraded
BIOREM Inc. (BRM.V) was upgraded to B from B- on 3/30/2023 due to a large increase in the total return index and volatility index.
BIOREM Inc. (BRM.V) was upgraded to B from B- on 3/30/2023 due to a large increase in the total return index and volatility index.
B
Buy
2/1/2023Upgraded
BIOREM Inc. (BRM.V) was upgraded to B- from C on 2/1/2023 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 353.3% from $128.7 to $583.4, earnings per share increased from $0.0078 to $0.0307, and EBIT increased 206.63% from $293.9 to $901.2.
BIOREM Inc. (BRM.V) was upgraded to B- from C on 2/1/2023 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 353.3% from $128.7 to $583.4, earnings per share increased from $0.0078 to $0.0307, and EBIT increased 206.63% from $293.9 to $901.2.
C
Hold
11/26/2021Downgrade
BIOREM Inc. (BRM.V) was downgraded to C from B- on 11/26/2021 due to a significant decline in the growth index, valuation index and efficiency index. EBIT declined 159.99% from $192.7 to -$115.6, net income declined 142.23% from $216.9 to -$91.6, and total revenue declined 20.83% from $4.59M to $3.63M.
BIOREM Inc. (BRM.V) was downgraded to C from B- on 11/26/2021 due to a significant decline in the growth index, valuation index and efficiency index. EBIT declined 159.99% from $192.7 to -$115.6, net income declined 142.23% from $216.9 to -$91.6, and total revenue declined 20.83% from $4.59M to $3.63M.
B
Buy
9/22/2021Upgraded
BIOREM Inc. (BRM.V) was upgraded to B- from C+ on 9/22/2021 due to a substantial increase in the total return index.
BIOREM Inc. (BRM.V) was upgraded to B- from C+ on 9/22/2021 due to a substantial increase in the total return index.
C
Hold
7/29/2021Upgraded
BIOREM Inc. (BRM.V) was upgraded to C+ from C on 7/29/2021 due to a significant increase in the growth index. EBIT increased 183.9% from -$363.4 to $304.9, earnings per share increased from -$0.0079 to $0.0057, and total revenue increased 69.39% from $2.71M to $4.59M.
BIOREM Inc. (BRM.V) was upgraded to C+ from C on 7/29/2021 due to a significant increase in the growth index. EBIT increased 183.9% from -$363.4 to $304.9, earnings per share increased from -$0.0079 to $0.0057, and total revenue increased 69.39% from $2.71M to $4.59M.
C
Hold
7/19/2021Downgrade
BIOREM Inc. (BRM.V) was downgraded to C from C+ on 7/19/2021 due to a decline in the volatility index and total return index.
BIOREM Inc. (BRM.V) was downgraded to C from C+ on 7/19/2021 due to a decline in the volatility index and total return index.
C
Hold
5/26/2021Downgrade
BIOREM Inc. (BRM.V) was downgraded to C+ from B- on 5/26/2021 due to a significant decline in the growth index, efficiency index and volatility index. EBIT declined 147.58% from $926.4 to -$440.8, net income declined 137.99% from $874.6 to -$332.3, and earnings per share declined from $0.0185 to $0.0079.
BIOREM Inc. (BRM.V) was downgraded to C+ from B- on 5/26/2021 due to a significant decline in the growth index, efficiency index and volatility index. EBIT declined 147.58% from $926.4 to -$440.8, net income declined 137.99% from $874.6 to -$332.3, and earnings per share declined from $0.0185 to $0.0079.
B
Buy
5/19/2021Downgrade
BIOREM Inc. (BRM.V) was downgraded to B- from B on 5/19/2021 due to a large decline in the total return index and volatility index.
BIOREM Inc. (BRM.V) was downgraded to B- from B on 5/19/2021 due to a large decline in the total return index and volatility index.
B
Buy
5/4/2021Upgraded
BIOREM Inc. (BRM.V) was upgraded to B from B- on 5/4/2021 due to an increase in the volatility index and efficiency index.
BIOREM Inc. (BRM.V) was upgraded to B from B- on 5/4/2021 due to an increase in the volatility index and efficiency index.
B
Buy
4/1/2021Upgraded
BIOREM Inc. (BRM.V) was upgraded to B- from C- on 4/1/2021 due to a significant increase in the growth index, valuation index and total return index. EBIT increased 551.87% from $195.5 to $1.27M, earnings per share increased from $0.003 to $0.0168, and total revenue increased 126.1% from $2.69M to $6.09M.
BIOREM Inc. (BRM.V) was upgraded to B- from C- on 4/1/2021 due to a significant increase in the growth index, valuation index and total return index. EBIT increased 551.87% from $195.5 to $1.27M, earnings per share increased from $0.003 to $0.0168, and total revenue increased 126.1% from $2.69M to $6.09M.
C
Hold
12/31/2020Upgraded
BIOREM Inc. (BRM.V) was upgraded to C- from D+ on 12/31/2020 due to a noticeable increase in the total return index, volatility index and valuation index.
BIOREM Inc. (BRM.V) was upgraded to C- from D+ on 12/31/2020 due to a noticeable increase in the total return index, volatility index and valuation index.
D
Sell
9/23/2020Upgraded
BIOREM Inc. (BRM.V) was upgraded to D+ from D on 9/23/2020 due to an increase in the total return index, volatility index and valuation index.
BIOREM Inc. (BRM.V) was upgraded to D+ from D on 9/23/2020 due to an increase in the total return index, volatility index and valuation index.
D
Sell
9/8/2020Downgrade
BIOREM Inc. (BRM.V) was downgraded to D from D+ on 9/8/2020 due to a decline in the volatility index.
BIOREM Inc. (BRM.V) was downgraded to D from D+ on 9/8/2020 due to a decline in the volatility index.
D
Sell
8/18/2020Upgraded
BIOREM Inc. (BRM.V) was upgraded to D+ from D on 8/18/2020 due to an increase in the solvency index and efficiency index. Total capital increased 5.67% from $8.78M to $9.28M.
BIOREM Inc. (BRM.V) was upgraded to D+ from D on 8/18/2020 due to an increase in the solvency index and efficiency index. Total capital increased 5.67% from $8.78M to $9.28M.
D
Sell
6/26/2020Downgrade
BIOREM Inc. (BRM.V) was downgraded to D from D+ on 6/26/2020 due to a large decline in the volatility index, solvency index and total return index.
BIOREM Inc. (BRM.V) was downgraded to D from D+ on 6/26/2020 due to a large decline in the volatility index, solvency index and total return index.
D
Sell
5/8/2020Downgrade
BIOREM Inc. (BRM.V) was downgraded to D+ from C on 5/8/2020 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 411.48% from $516.4 to -$1.61M, earnings per share declined from $0.0137 to -$0.0264, and EBIT declined 282% from $513.8 to -$935.1.
BIOREM Inc. (BRM.V) was downgraded to D+ from C on 5/8/2020 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 411.48% from $516.4 to -$1.61M, earnings per share declined from $0.0137 to -$0.0264, and EBIT declined 282% from $513.8 to -$935.1.
C
Hold
4/24/2020Downgrade
BIOREM Inc. (BRM.V) was downgraded to C from C+ on 4/24/2020 due to a noticeable decline in the total return index, solvency index and volatility index.
BIOREM Inc. (BRM.V) was downgraded to C from C+ on 4/24/2020 due to a noticeable decline in the total return index, solvency index and volatility index.
C
Hold
3/18/2020Downgrade
BIOREM Inc. (BRM.V) was downgraded to C+ from B on 3/18/2020 due to a noticeable decline in the total return index and volatility index.
BIOREM Inc. (BRM.V) was downgraded to C+ from B on 3/18/2020 due to a noticeable decline in the total return index and volatility index.
B
Buy
3/3/2020Upgraded
BIOREM Inc. (BRM.V) was upgraded to B from B- on 3/3/2020 due to a noticeable increase in the total return index, valuation index and volatility index.
BIOREM Inc. (BRM.V) was upgraded to B from B- on 3/3/2020 due to a noticeable increase in the total return index, valuation index and volatility index.
B
Buy
1/16/2020Upgraded
BIOREM Inc. (BRM.V) was upgraded to B- from C+ on 1/16/2020 due to an increase in the total return index and volatility index.
BIOREM Inc. (BRM.V) was upgraded to B- from C+ on 1/16/2020 due to an increase in the total return index and volatility index.
C
Hold
12/17/2019Upgraded
BIOREM Inc. (BRM.V) was upgraded to C+ from C on 12/17/2019 due to a significant increase in the growth index, solvency index and volatility index. EBIT increased 199.24% from $171.7 to $513.8, earnings per share increased from $0.005 to $0.0137, and operating cash flow increased 95.08% from -$703.4 to -$34.6.
BIOREM Inc. (BRM.V) was upgraded to C+ from C on 12/17/2019 due to a significant increase in the growth index, solvency index and volatility index. EBIT increased 199.24% from $171.7 to $513.8, earnings per share increased from $0.005 to $0.0137, and operating cash flow increased 95.08% from -$703.4 to -$34.6.
C
Hold
8/2/2019Downgrade
BIOREM Inc. (BRM.V) was downgraded to C from C+ on 8/2/2019 due to a decline in the volatility index and total return index.
BIOREM Inc. (BRM.V) was downgraded to C from C+ on 8/2/2019 due to a decline in the volatility index and total return index.
C
Hold
7/18/2019Downgrade
BIOREM Inc. (BRM.V) was downgraded to C+ from B- on 7/18/2019 due to a noticeable decline in the total return index, solvency index and valuation index.
BIOREM Inc. (BRM.V) was downgraded to C+ from B- on 7/18/2019 due to a noticeable decline in the total return index, solvency index and valuation index.
B
Buy
6/4/2019Upgraded
BIOREM Inc. (BRM.V) was upgraded to B- from C+ on 6/4/2019 due to an increase in the total return index and volatility index.
BIOREM Inc. (BRM.V) was upgraded to B- from C+ on 6/4/2019 due to an increase in the total return index and volatility index.
C
Hold
5/31/2019Upgraded
BIOREM Inc. (BRM.V) was upgraded to C+ from C on 5/31/2019 due to a major increase in the valuation index, solvency index and volatility index.
BIOREM Inc. (BRM.V) was upgraded to C+ from C on 5/31/2019 due to a major increase in the valuation index, solvency index and volatility index.
C
Hold
7/31/2018Downgrade
BIOREM Inc. (BRM.V) was downgraded to C from C+ on 7/31/2018 due to a decline in the total return index, growth index and solvency index. EBIT declined 140.31% from $785.2 to -$316.5, earnings per share declined from $0.0236 to -$0.0034, and total revenue declined 54.29% from $6.72M to $3.07M.
BIOREM Inc. (BRM.V) was downgraded to C from C+ on 7/31/2018 due to a decline in the total return index, growth index and solvency index. EBIT declined 140.31% from $785.2 to -$316.5, earnings per share declined from $0.0236 to -$0.0034, and total revenue declined 54.29% from $6.72M to $3.07M.
C
Hold
3/27/2018Upgraded
BIOREM Inc. (BRM.V) was upgraded to C+ from C on 3/27/2018 due to a significant increase in the valuation index, growth index and efficiency index. Operating cash flow increased 9,939.29% from $5.6 to $562.2, earnings per share increased from $0.008 to $0.0222, and EBIT increased 91.21% from $357.2 to $683.
BIOREM Inc. (BRM.V) was upgraded to C+ from C on 3/27/2018 due to a significant increase in the valuation index, growth index and efficiency index. Operating cash flow increased 9,939.29% from $5.6 to $562.2, earnings per share increased from $0.008 to $0.0222, and EBIT increased 91.21% from $357.2 to $683.
C
Hold
8/31/2017Upgraded
BIOREM Inc. (BRM.V) was upgraded to C from C- on 8/31/2017 due to a significant increase in the total return index, growth index and efficiency index. Total revenue increased 81.13% from $2.33M to $4.22M, and total capital increased 9.03% from $4.02M to $4.38M.
BIOREM Inc. (BRM.V) was upgraded to C from C- on 8/31/2017 due to a significant increase in the total return index, growth index and efficiency index. Total revenue increased 81.13% from $2.33M to $4.22M, and total capital increased 9.03% from $4.02M to $4.38M.
C
Hold
1/23/2017Upgraded
BIOREM Inc. (BRM.V) was upgraded to C- from D+ on 1/23/2017 due to an increase in the total return index, growth index and volatility index. EBIT increased 273.53% from -$129.2 to $224.2, earnings per share increased from -$0.0078 to $0.0052, and total revenue increased 34.3% from $2.28M to $3.07M.
BIOREM Inc. (BRM.V) was upgraded to C- from D+ on 1/23/2017 due to an increase in the total return index, growth index and volatility index. EBIT increased 273.53% from -$129.2 to $224.2, earnings per share increased from -$0.0078 to $0.0052, and total revenue increased 34.3% from $2.28M to $3.07M.
D
Sell
11/10/2016Downgrade
BIOREM Inc. (BRM.V) was downgraded to D+ from C- on 11/10/2016 due to a noticeable decline in the total return index, volatility index and solvency index.
BIOREM Inc. (BRM.V) was downgraded to D+ from C- on 11/10/2016 due to a noticeable decline in the total return index, volatility index and solvency index.
C
Hold
8/19/2016Upgraded
BIOREM Inc. (BRM.V) was upgraded to C- from D+ on 8/19/2016 due to an increase in the volatility index and valuation index.
BIOREM Inc. (BRM.V) was upgraded to C- from D+ on 8/19/2016 due to an increase in the volatility index and valuation index.
D
Sell
8/4/2016Downgrade
BIOREM Inc. (BRM.V) was downgraded to D+ from C- on 8/4/2016 due to a decline in the volatility index.
BIOREM Inc. (BRM.V) was downgraded to D+ from C- on 8/4/2016 due to a decline in the volatility index.
C
Hold
7/28/2016Downgrade
BIOREM Inc. (BRM.V) was downgraded to C- from C+ on 7/28/2016 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 207.15% from -$96.5 to -$296.4, earnings per share declined from $0.0073 to -$0.0078, and net income declined 132.15% from $272.5 to -$87.6.
BIOREM Inc. (BRM.V) was downgraded to C- from C+ on 7/28/2016 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 207.15% from -$96.5 to -$296.4, earnings per share declined from $0.0073 to -$0.0078, and net income declined 132.15% from $272.5 to -$87.6.
C
Hold
5/20/2016Upgraded
BIOREM Inc. (BRM.V) was upgraded to C+ from D+ on 5/20/2016 due to a substantial increase in the growth index, efficiency index and volatility index. Net income increased 192.07% from $93.3 to $272.5, EBIT increased 135.27% from $194.5 to $457.6, and earnings per share increased from $0.0056 to $0.0073.
BIOREM Inc. (BRM.V) was upgraded to C+ from D+ on 5/20/2016 due to a substantial increase in the growth index, efficiency index and volatility index. Net income increased 192.07% from $93.3 to $272.5, EBIT increased 135.27% from $194.5 to $457.6, and earnings per share increased from $0.0056 to $0.0073.
D
Sell
5/10/2016Downgrade
BIOREM Inc. (BRM.V) was downgraded to D+ from C- on 5/10/2016 due to a decline in the volatility index and efficiency index. Net income declined 61.59% from $242.9 to $93.3, and total capital declined 4.81% from $3.64M to $3.47M.
BIOREM Inc. (BRM.V) was downgraded to D+ from C- on 5/10/2016 due to a decline in the volatility index and efficiency index. Net income declined 61.59% from $242.9 to $93.3, and total capital declined 4.81% from $3.64M to $3.47M.
C
Hold
3/11/2016Downgrade
BIOREM Inc. (BRM.V) was downgraded to C- from C+ on 3/11/2016 due to a significant decline in the volatility index, total return index and valuation index.
BIOREM Inc. (BRM.V) was downgraded to C- from C+ on 3/11/2016 due to a significant decline in the volatility index, total return index and valuation index.
C
Hold
1/8/2016Downgrade
BIOREM Inc. (BRM.V) was downgraded to C+ from B- on 1/8/2016 due to a large decline in the total return index.
BIOREM Inc. (BRM.V) was downgraded to C+ from B- on 1/8/2016 due to a large decline in the total return index.
B
Buy
11/23/2015Downgrade
BIOREM Inc. (BRM.V) was downgraded to B- from B on 11/23/2015 due to a large decline in the total return index and solvency index.
BIOREM Inc. (BRM.V) was downgraded to B- from B on 11/23/2015 due to a large decline in the total return index and solvency index.
B
Buy
11/6/2015Upgraded
BIOREM Inc. (BRM.V) was upgraded to B from B- on 11/6/2015 due to a significant increase in the valuation index, solvency index and volatility index. Debt to equity declined from 3.54 to 1.94.
BIOREM Inc. (BRM.V) was upgraded to B from B- on 11/6/2015 due to a significant increase in the valuation index, solvency index and volatility index. Debt to equity declined from 3.54 to 1.94.
B
Buy
9/29/2015Upgraded
BIOREM Inc. (BRM.V) was upgraded to B- from C+ on 9/29/2015 due to an increase in the valuation index and total return index.
BIOREM Inc. (BRM.V) was upgraded to B- from C+ on 9/29/2015 due to an increase in the valuation index and total return index.
C
Hold
9/14/2015Downgrade
BIOREM Inc. (BRM.V) was downgraded to C+ from B- on 9/14/2015 due to a decline in the valuation index.
BIOREM Inc. (BRM.V) was downgraded to C+ from B- on 9/14/2015 due to a decline in the valuation index.
B
Buy
8/28/2015Upgraded
BIOREM Inc. (BRM.V) was upgraded to B- from C on 8/28/2015 due to a significant increase in the efficiency index, growth index and solvency index. Operating cash flow increased 364.38% from $159.2 to $739.3, debt to equity declined from 8.06 to 3.54, and EBIT increased 41.03% from $483.5 to $681.9.
BIOREM Inc. (BRM.V) was upgraded to B- from C on 8/28/2015 due to a significant increase in the efficiency index, growth index and solvency index. Operating cash flow increased 364.38% from $159.2 to $739.3, debt to equity declined from 8.06 to 3.54, and EBIT increased 41.03% from $483.5 to $681.9.
C
Hold
8/13/2015Upgraded
BIOREM Inc. (BRM.V) was upgraded to C from C- on 8/13/2015 due to a major increase in the total return index.
BIOREM Inc. (BRM.V) was upgraded to C from C- on 8/13/2015 due to a major increase in the total return index.
C
Hold
7/24/2015Upgraded
BIOREM Inc. (BRM.V) was upgraded to C- from D+ on 7/24/2015 due to a substantial increase in the total return index and volatility index.
BIOREM Inc. (BRM.V) was upgraded to C- from D+ on 7/24/2015 due to a substantial increase in the total return index and volatility index.
D
Sell
6/2/2015Upgraded
BIOREM Inc. (BRM.V) was upgraded to D+ from D on 6/2/2015 due to a major increase in the volatility index, growth index and valuation index. EBIT increased 462.16% from $99.9 to $561.6, and total revenue increased 8.11% from $3.49M to $3.78M.
BIOREM Inc. (BRM.V) was upgraded to D+ from D on 6/2/2015 due to a major increase in the volatility index, growth index and valuation index. EBIT increased 462.16% from $99.9 to $561.6, and total revenue increased 8.11% from $3.49M to $3.78M.
D
Sell
6/16/2014Downgrade
BIOREM Inc. (BRM.V) was downgraded to D from D+ on 6/16/2014 due to a substantial decline in the volatility index.
BIOREM Inc. (BRM.V) was downgraded to D from D+ on 6/16/2014 due to a substantial decline in the volatility index.
D
Sell
6/2/2014Downgrade
BIOREM Inc. (BRM.V) was downgraded to D+ from C+ on 6/2/2014 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.0147 to -$0.0363, EBIT declined 207.84% from $368.6 to -$397.5, and operating cash flow declined 172.31% from $1.34M to -$966.3.
BIOREM Inc. (BRM.V) was downgraded to D+ from C+ on 6/2/2014 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.0147 to -$0.0363, EBIT declined 207.84% from $368.6 to -$397.5, and operating cash flow declined 172.31% from $1.34M to -$966.3.
C
Hold
4/11/2014Upgraded
BIOREM Inc. (BRM.V) was upgraded to C+ from C on 4/11/2014 due to a noticeable increase in the valuation index, growth index and solvency index. Operating cash flow increased 2,643.94% from $48.7 to $1.34M, earnings per share increased from $0.0105 to $0.0147, and debt to equity declined from 5.67 to 4.06.
BIOREM Inc. (BRM.V) was upgraded to C+ from C on 4/11/2014 due to a noticeable increase in the valuation index, growth index and solvency index. Operating cash flow increased 2,643.94% from $48.7 to $1.34M, earnings per share increased from $0.0105 to $0.0147, and debt to equity declined from 5.67 to 4.06.
